InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,187.70
(
0.13%
)
US TECH 100
17,617.63
(
0.04%
)
Dow Jones
38,884.26
(
0.08%
)
Brent Oil
82.83
(
-0.05%
)
Bitcoin
62,406.71
(
0.12%
)
Post# of 251748
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 828
Posts 119591
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 184044

Monday, 06/26/2017 9:48:34 AM

Monday, June 26, 2017 9:48:34 AM

Post# of 251748
NEOT -70% on failed phase-2 in “double-chin” fat:

https://finance.yahoo.com/news/neothetics-announces-top-line-results-120000776.html

Neothetics…today announced top-line safety and efficacy results from its Phase 2 proof-of-concept trial, LIPO-202-CL-31, for the reduction of submental subcutaneous fat. LIPO-202 did not demonstrate improvement on any efficacy measurements or separation from placebo. LIPO-202 continued to show a benign safety profile.

‘rkrw’ and I disparaged this company’s prospects at the time of the IPO (#msg-108341768, #msg-108345338).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up